22VAH835: A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer whose Disease Progressed After Prior Endocrine Based Treated for A

Principal Investigator

Linda Vahdat

Study Number

STUDY02001835

Summary

This study is for patients with ER(+)/HER2(-) recurrent or metastatic breast cancer that cannot be treated by surgery or radiation therapy and has worsened or not responded to other standard treatments. Participants will have a 50/50 chance of either receiving the study drug ARV-471 or the comparison drug fulvestrant. The purpose of this study is to determine how well the study drug works in comparison to fulvestrant to determine which works better at treating this type of breast cancer.

Phase

III

Available at the following location(s)

  • Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms